Welcome to LookChem.com Sign In|Join Free

CAS

  • or

126147-70-4

Post Buying Request

126147-70-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

126147-70-4 Usage

Chemical Properties

Colourless Thick-Oil

Uses

N-Phenoxycarbonyl-L-valine (cas# 126147-70-4) is a compound useful in organic synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 126147-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,1,4 and 7 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 126147-70:
(8*1)+(7*2)+(6*6)+(5*1)+(4*4)+(3*7)+(2*7)+(1*0)=114
114 % 10 = 4
So 126147-70-4 is a valid CAS Registry Number.

126147-70-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-3-methyl-2-(phenoxycarbonylamino)butanoic acid

1.2 Other means of identification

Product number -
Other names carbobenzoxy-L-valine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:126147-70-4 SDS

126147-70-4Relevant articles and documents

An Efficient Synthesis of (4S)-(-)-4-Isopropyl-2-oxazolidinone

Wuts, Peter G. M.,Pruitt, Lynn E.

, p. 622 - 623 (1989)

A new, efficient, cost-effective method for the preparation of the Evans'chiral auxiliary (4S)-4-isopropyl-2-oxazolidinone (4) is described.A Schotten-Baumann acylation of valine with phenyl carbonochloridate quantitatively affords the protected valine, which is then reduced with borane in tetrahydrofuran to give an alcohol.Cyclization with a catalytic amount of potassium tert-butoxide gives 4 in 81percent overall yield and in 41-43percent after crystallization from ethyl acetate/n-hexane.

A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus

Yeh, Teng-Kuang,Kang, Iou-Jiun,Hsu, Tsu-An,Lee, Yen-Chun,Lee, Chung-Chi,Hsu, Sheng-Ju,Tian, Ya-Wen,Yang, Hui-Yun,Chen, Chiung-Tong,Chao, Yu-Sheng,Yueh, Andrew,Chern, Jyh-Haur

, p. 245 - 268 (2019/02/19)

A medicinal chemistry program based on the small-molecule HCV NS5A inhibitor daclatasvir has led to the discovery of dimeric phenylthiazole compound 8, a novel and potent HCV NS5A inhibitor. The subsequent SAR studies and optimization revealed that the cycloalkyl amide derivatives 27a-29a exhibited superior potency against GT1b with GT1b EC50 values at picomolar concentration. Interestingly, high diastereospecificity for HCV inhibition was observed in this class with the (1R,2S,1′R,2′S) diastereomer displaying the highest GT1b inhibitory activity. The best inhibitor 27a was found to be 3-fold more potent (GT1b EC50 = 0.003 nM) than daclatasvir (GT1b EC50 = 0.009 nM) against GT1b, and no detectable in vitro cytotoxicity was observed (CC50 > 50 μM). Pharmacokinetic studies demonstrated that compound 27a had an excellent pharmacokinetic profiles with a superior oral exposure and desired bioavailability after oral administration in both rats and dogs, and therefore it was selected as a developmental candidate for the treatment of HCV infection.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

-

Page/Page column 151, (2014/09/16)

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

Retroviral protease inhibiting compounds

-

Page 62, (2010/01/31)

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 126147-70-4